JW Holdings Corp is a Korea-based company principally engaged in the production and sale of pharmaceuticals. The Company is principally engaged in the production and sale of pharmaceuticals such as antibiotics, antifungal agents, blood and body fluids substitutes, hyperlipidemia drugs, electrolyte additives, angina pills and digestive medicines. The Company is also engaged in the manufacture and sale of diagnostic equipment for hematology, immunology and others. In addition, the Company is engaged in the holding businesses.

Employees

114

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
01/11/26	₩3,880.00	-2.14%	41,920
30/10/26	₩3,965.00	-0.88%	56,661
29/10/26	₩4,000.00	+1.78%	40,932
28/10/26	₩3,930.00	+0.64%	32,133
27/10/26	₩3,905.00	+2.09%	31,180

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 02/11/2026			5-day change	1st Jan Change
3,880.00 ^KRW	-2.14%		-0.51%	+8.08%

08-14	JW Holdings Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	JW Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	268B 201M 180M 166M 150M 281M 19.11B 286M 1.98B 794M 10.05B 755M 739M 31.7B	P/E 2024	3.45x	P/E 2025	4.27x
Enterprise Value	539B 404M 362M 333M 301M 563M 38.34B 574M 3.97B 1.59B 20.17B 1.52B 1.48B 63.6B	EV / Sales 2024	0.65x	EV / Sales 2025	0.53x
Free-Float	39.41%	Yield 2024	5.13%	Yield 2025	5.99%

08-14	JW Holdings Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	JW Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-13	JW Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-04	JW Holdings Corporation announces Annual dividend, payable on April 24, 2026	CI
11-14	JW Holdings Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-03	Jw Holdings Q3 operating profit 5 billion won, up 38.4% from year earlier	RE
14/08/25	JW Holdings Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
31/07/25	Jw Holdings Q2 operating profit 3.4 billion won, down 82% from year earlier	RE
03/07/25	Sound Smithy Co Ltd announced that it has received KRW 200 million in funding from JW Holdings Corporation	CI
25/06/25	Sound Smithy Co Ltd announced that it expects to receive KRW 200 million in funding from JW Holdings Corporation	CI
25/06/25	Tranche Update on JW Holdings Corporation's Equity Buyback Plan announced on March 24, 2025.	CI
25/06/25	Tranche Update on JW Holdings Corporation's Equity Buyback Plan announced on March 24, 2025.	CI
23/06/25	JW Holdings Corporation's Equity Buyback announced on March 24, 2025 has expired with 714,439 shares, representing 1.02% for KRW 2,500 million.	CI

04/10/23	Les valeurs à suivre aujourd'hui à la Bourse de Paris - Mercredi 4 octobre 2023
04/10/23	Kering : Seán McGirr nommé Directeur de la Création d'Alexander McQueen
03/10/23	Kering : nouveau directeur création chez Alexander McQueen
03/10/23	Kering nomme Seán McGirr directeur de la création chez Alexander McQueen
18/08/23	El Kospi de Corea cae un 0,6%, su mayor racha de pérdidas desde junio de 2022 -- Market Talk

JW Holdings Corporation Share Price

Stocks

A096760

KR7096760004

Pharmaceuticals

Valuation: JW Holdings Corporation

Chart: JW Holdings Corporation

Latest news: JW Holdings Corporation

News in other languages: JW Holdings Corporation

Quotes and Performance

Price Extremes

Managers and Directors: JW Holdings Corporation

Latest insider transactions

Generic Pharmaceuticals

Financials

Company Profile

Quotes

1 day	-2.14%
1 week	-0.51%
Current month	-2.14%
1 month	-10.91%
3 months	+3.47%
6 months	-9.35%
Current year	+8.08%

1 week	3,825	4,070
1 month	3,815	4,300
Current year	3,300	4,720
1 year	3,195	4,720
3 years	2,650	4,720
5 years	2,536.65	4,720
10 years	2,536.65	9,991.64

Manager	Title	Age	Since
Seong-Nam Cha CEO	Chief Executive Officer	69	26/03/2024
Kyung-Ha Lee CEO	Chief Executive Officer	63	-
Ji-Woo Choi DFI	Director of Finance/CFO	60	26/03/2020

Director	Title	Age	Since
Kyung-Ha Lee CHM	Chairman	63	-
Chan-Yeop Yeom BRD	Director/Board Member	64	26/03/2020
Ji-Woo Choi BRD	Director/Board Member	60	26/03/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
07/02/24	Sung-Kweon Han	Free	Chief Executive Officer	215	0.0003%
07/02/24	Gui-eung Song	Free		4	0.0000%	-
07/02/24	Kyung-Ha Lee	Free	Chief Executive Officer	412,069	0.5574%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JW HOLDINGS CORPORATION	-2.14%	-0.51%	+19.20%	+19.03%	206M
ELI LILLY AND COMPANY	-0.72%	+10.09%	+57.07%	+142.67%	1,263B
JOHNSON & JOHNSON	-1.82%	+0.84%	+44.18%	+78.74%	658B
ABBVIE INC.	-2.03%	+0.32%	+35.72%	+100.80%	521B
ROCHE HOLDING AG	-1.62%	0.00%	+52.79%	+66.49%	391B
MERCK & CO., INC.	-0.78%	+5.38%	+79.63%	+44.07%	369B
NOVARTIS AG	-1.76%	+3.11%	+32.10%	+55.26%	307B
ASTRAZENECA PLC	-0.77%	+7.70%	+11.97%	+33.60%	290B
AMGEN INC.	-0.70%	+3.97%	+56.02%	+73.40%	252B
GILEAD SCIENCES, INC.	-1.00%	+5.83%	+37.60%	+106.74%	212B
Average	-1.34%	+5.24%	+42.63%	+72.08%	426.21B
Weighted average by Cap.	-1.25%	+6.60%	+48.13%	+92.56%

	2024	2025
Net sales	888B 666M 596M 548M 497M 929M 63.2B 946M 6.54B 2.62B 33.24B 2.5B 2.44B 105B	970B 727M 651M 599M 543M 1.01B 69.02B 1.03B 7.14B 2.87B 36.31B 2.73B 2.67B 115B
Net income	62.62B 46.95M 42.05M 38.68M 35.04M 65.5M 4.46B 66.73M 461M 185M 2.34B 176M 172M 7.39B	58.5B 43.86M 39.28M 36.14M 32.74M 61.2M 4.16B 62.35M 431M 173M 2.19B 165M 161M 6.91B
Net Debt	362B 271M 243M 223M 202M 378M 25.75B 385M 2.66B 1.07B 13.54B 1.02B 996M 42.71B	270B 203M 181M 167M 151M 283M 19.23B 288M 1.99B 799M 10.11B 760M 744M 31.9B